Exposure –response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

ConclusionExposure –response relationships for efficacy were inconsistent across exposure metrics; model-predicted cycle 1Cmin showed the strongest exposure –response trend. TheQ1 subgroup based on model-predicted cycle 1Cmin had numerically similar or better OS and PFS versus control following covariate adjustment. The approved T-DM1 dose (3.6  mg/kg every 3 weeks) has a positive benefit–risk ratio versus control, even for the T-DM1Q1 subgroup.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research